CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $6.2M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
18.65MILS6.20M · vs all stocks (USD)
Revenue (TTM)
0.00ILAvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.5380xvs all stocks
52-Week Change
-71.43%vs all stocks
Market Capitalization
18.65MILS6.20M · vs all stocks (USD)
Enterprise Value
0.00ILSvs all stocks (USD)
Price to Book (MRQ)
2.00xvs Biotechnology peers
Enterprise to EBITDA
-1.58xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-19.55%vs Biotechnology peers
Return on Equity (TTM)
-123.35%vs Biotechnology peers
Revenue (TTM)
0.00ILAvs all stocks (USD)
Revenue per Share (TTM)
0.00ILAUpdated Aug 7, 2026Net Income (TTM)
-26.39MILA-8.78M · vs all stocks (USD)
Operating Cash Flow (TTM)
-5.66MILA-1.88M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-26.39MILA-8.78M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-55.00KUSDFY2025 · Dec 31, 2025Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-6.98MUSDvs all stocks (USD)
Pre-tax Income
-26.49MUSDFY2025 · Dec 31, 2025Net Income
-26.49MUSDFY2025 · Dec 31, 2025EBIT
-26.45MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-7.49MUSDFY2025 · Dec 31, 2025Research & Development
3.73MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
2.98MUSDFY2025 · Dec 31, 2025Other Operating Expenses
59.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
227.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
39.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
0.5496USDFY2025 · Dec 31, 2025EPS (Diluted)
0.5496USDFY2025 · Dec 31, 2025Basic Shares Outstanding
48.01MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
48.01MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-26.49MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
106.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
-26.34MUSDFY2025 · Dec 31, 2025Free Cash Flow
-26.35MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
8.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-26.49MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
203.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
309.00KUSDFY2025 · Dec 31, 2025Other Non-cash Items
-966.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
450.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
153.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-9.00KUSDFY2025 · Dec 31, 2025Sale of Investments
458.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
446.00KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-217.00KUSDFY2025 · Dec 31, 2025Common Dividends Paid
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-820.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
2.12MUSDFY2025 · Dec 31, 2025Shares Outstanding
1.86BSharesUpdated Aug 7, 2026Float Shares
1.85BSharesUpdated Aug 7, 2026% Held by Insiders
0.05%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash per Share (MRQ)
0.0030ILAUpdated Aug 7, 2026Total Debt to Equity (MRQ)
0.0190xvs Biotechnology peers
Current Ratio (MRQ)
1.48xvs Biotechnology peers
Book Value per Share (MRQ)
0.0050ILAUpdated Aug 7, 2026Total Assets
17.57MUSDvs all stocks (USD)
Total Current Assets
9.87MUSDFY2025 · Dec 31, 2025Total Liabilities
7.91MUSDFY2025 · Dec 31, 2025Total Non-current Assets
7.71MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
160.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
7.75MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
8.72MUSDFY2025 · Dec 31, 2025Other Short-term Investments
857.00KUSDFY2025 · Dec 31, 2025Accounts Payable
2.07MUSDFY2025 · Dec 31, 2025Short-term Debt
244.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
4.07MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-171.08MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
9.66MUSDvs all stocks (USD)
52-Week High
3.90ILAUpdated Aug 7, 202652-Week Change
-71.43%vs all stocks
Beta
-0.5380xvs all stocks
50-Day MA
0.9604ILAUpdated Aug 7, 2026200-Day MA
1.07ILAUpdated Aug 7, 2026Avg 10-Day Volume
20.20KSharesUpdated Aug 7, 2026Avg 30-Day Volume
197.15KSharesUpdated Aug 7, 2026Diluted EPS (TTM)
4.94ILAUpdated Aug 7, 2026Other Income / Expense
-18.77MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $6.2M, lower than 95% of all stocks globallySignificant
Market cap (USD): 6,202,419.647Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
XTL Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
TheracryF PLC
Tier 1ProductionApproval-Gated PipelineRule
Nuformix Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Futura Medical plc
Tier 1ProductionApproval-Gated PipelineRule
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk